Children And Family Dentistry Of South Attleboro Dentist - Endodontics Medicare: Not Enrolled in Medicare Practice Location: 720 Washington St, South Attleboro, MA 02703 Phone: 508-761-7700 Fax: 508-761-5700 |
James M Phelan Dmd Pc Dentist Medicare: Not Enrolled in Medicare Practice Location: 3 Howarth Ave, South Attleboro, MA 02703 Phone: 508-761-5320 |
Advanced Dental Care Inc. Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 720 Washington St, South Attleboro, MA 02703 Phone: 508-761-7700 Fax: 508-761-5700 |
Millerlung Dental Group Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 288 Highland Ave, South Attleboro, MA 02703 Phone: 508-399-8130 Fax: 508-761-5280 |
Gentle Dental Attleboro Clinic/Center - Dental Medicare: Not Enrolled in Medicare Practice Location: 1144 Newport Ave, South Attleboro, MA 02703 Phone: 508-223-3900 |
George Family Orthodontics Inc Dentist - Orthodontics and Dentofacial Orthopedics Medicare: Not Enrolled in Medicare Practice Location: 288 Highland Ave, South Attleboro, MA 02703 Phone: 508-761-5230 |
James M Phelan, Dmd Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 3 Howarth Ave, South Attleboro, MA 02703 Phone: 508-761-5320 |
News Archive
Autism Speaks, the world's leading autism science and advocacy organization, today announced awards totaling $685,968 funding new research in areas of high priority that will advance understanding and treatment of autism spectrum disorders (ASD).
Caffeine can help those working shifts or nights to make fewer errors, according to a new study by Cochrane researchers. The findings have implications for health workers and for any industry relying on shift or night work, such as transportation.
Scientists at Washington University School of Medicine in St. Louis have discovered what appears to be a potent stimulator of new bone growth. The finding could lead to new treatments for osteoporosis and other diseases that occur when the body doesn't make enough bone.
Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.
› Verified 2 days ago